Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain gives an insight into proteasome-based approaches in treating elderly patients with multiple myeloma. Proteasome inhibitors such as bortezomib, ixazomib and carfilzomib can be used in combination with corticosteroids or monoclonal antibodies to improve outcomes in elderly patients. Bortezomib in combination with the standard of care melphalan and prednisone has been shown to improve patient survival and proteasome inhibitors also have the potential to be used in combination with immunomodulatory drugs. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

свернуть